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OBJECTIVES The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
functional status substudy aimed to test the hypothesis that functional status is similar in
rate-control and rhythm-control strategies.
BACKGROUND Randomized studies, including the AFFIRM study, have failed to demonstrate survival
benefits between rate-control and rhythm-control strategies for atrial fibrillation (AF).
However, AF may cause functional capacity or cognitive impairment that might justify
maintenance of sinus rhythm.
METHODS Investigators of the AFFIRM study enrolled 4,060 patients with AF who required long-term
therapy and who were 65 years of age or older or who had another risk factor for stroke or
death. New York Heart Association functional class (NYHA-FC) and Canadian Cardiovas-
cular Society Angina Classification were assessed at initial and each follow-up visit. From 22
randomly chosen functional status substudy sites, 245 participants underwent 6-min walk
tests and Mini-Mental State Examination (MMSE) at initial, two-month, and yearly visits.
Patients were assigned randomly to rate-controlling drugs, allowing AF to persist, or
rhythm-controlling antiarrhythmic drugs, to maintain sinus rhythm.
RESULTS The NYHA-FC worsened with time in both rate-control and rhythm-control groups, with no
differences between groups. Presence of AF was associated with worse NYHA-FC (p 0.0001).
No differences were observed in Canadian Cardiovascular Society Angina Classification or
MMSE scores. Six-minute walk distance improved over time in both study arms. On average,
walk distance was 94 feet greater in the rhythm-control group (adjusted p  0.049).
CONCLUSIONS Modest improvement in 6-min walk distance was noted in the rhythm-control arm. Presence
of AF was associated with worse NYHA-FC. No difference in cognitive function was
detected. (J Am Coll Cardiol 2005;46:1891–9) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.040Cardiology Foundation
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Rtrial fibrillation (AF) may cause significant morbidity,
ncluding the impairment of functional status. Exercise
apacity may be limited by decreases in cardiac output from
See page 1900
oorly controlled ventricular rates, loss of atrioventricular
ynchrony, or disability from stroke or other thromboem-
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ational Institutes of Health, Bethesda, Maryland. The AFFIRM Investigators and
heir affiliations are listed in reference 26.a
Manuscript received April 25, 2005; revised manuscript received July 5, 2005,
ccepted July 11, 2005.olic complications (1–3). Additionally, impaired cognitive
unction has been reported (4–9), potentially related to
ilent embolic strokes or decreases in cerebral blood flow
10,11).
Functional status may be assessed by standard indices,
ncluding the New York Heart Association classification
f functional capacity (NYHA-FC) (12,13) or Canadian
ardiovascular Society angina classification (CCS-AC)
13,14). Six-minute walk tests have been used to assess
unctional status in patients with cardiovascular and
ulmonary diseases, including congestive heart failure
CHF) (15–17) and AF (18). The Mini-Mental State
xamination (MMSE), a standardized test of cognition
19 –21), has been used in intervention studies to monitor
reatment effects and in AF studies to evaluate cognition
4 – 8,22).
The Atrial Fibrillation Follow-up Investigation of
hythm Management (AFFIRM) study (23,24), whichssigned patients with AF randomly to rate-control versus
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Functional Status in the AFFIRM Study November 15, 2005:1891–9hythm-control strategies, showed no significant difference
n mortality between these approaches for AF. In light of
his finding, morbidity or other clinical factors, such as
unctional status, may determine which strategy is most
ppropriate for patients with AF.
Functional status was assessed in a prospective, prespeci-
ed substudy of AFFIRM study patients to test the hypoth-
sis that functional status is similar in rate-control and
hythm-control strategies. The substudy aimed to deter-
ine whether differences in functional status outcome
easurements were associated with randomized strategy or
hythm present at testing. The NYHA-FC and CCS-AC
ere assessed in all patients at enrollment and all follow-up
isits. Serial 6-min walk tests and MMSEs were performed
n a subgroup of patients.
ETHODS
esign of the AFFIRM study. In the AFFIRM study, a
ulticenter, randomized trial comparing rate-control versus
hythm-control strategies for the treatment of AF (23–26),
atients from 213 U.S. and Canadian sites were enrolled
rom November 1995 through October 1999. Follow-up
nded October 31, 2001.
Patients included in the study were 65 years of age or
ad another risk factor for stroke or death. Documentation
as required that sufficient AF had been present to require
ong-term therapy. Patients were candidates for anticoagu-
ation therapy and eligible to undergo trials with at least two
rugs in both treatment strategies. The protocol was ap-
roved by each site’s institutional review board. All patients
ave informed, written consent to participate in the main
tudy and, if participating in the functional status substudy,
lso for this substudy.
In the rate-control strategy, beta-blockers, calcium chan-
el blockers (verapamil or diltiazem), and/or digoxin were
sed at the treating physician’s discretion. Heart rate control
as assessed at rest and exercise, with target heart rates
f 80 beats/min at rest and 110 beats/min during the
-min walk tests (23–26).
In the rhythm-control strategy, antiarrhythmic drug use
as selected by the treating clinician with specific guidelines
Abbreviations and Acronyms
AF  atrial fibrillation
AFFIRM  Atrial Fibrillation Follow-up Investigation
of Rhythm Management
CAD  coronary artery disease
CCS-AC  Canadian Cardiovascular Society angina
classification
CHF  congestive heart failure
LVEF  left ventricular ejection fraction
MMSE  Mini-Mental State Examination
NYHA-FC  New York Heart Association functional
classor the use of antiarrhythmic drugs in the protocol (25). fatients in the rhythm-control arm underwent cardiover-
ion as needed. Anticoagulation was used in both strategies
ccording to published guidelines.
unctional status substudy populations. The NYHA-
C, CCS-AC, and cardiac rhythm were assessed on all
FFIRM study patients at an initial and every follow-up
isit. Prospective substudies of functional status and quality
f life were conducted. Of 213 clinical sites participating in
he AFFIRM study, 25% were selected randomly to partic-
pate in the quality of life substudy (27). Of the quality of
ife substudy sites, 22 sites randomly were selected to
articipate in the functional status substudy. Functional
tatus substudy patients underwent the 6-min walk test and
MSE at the initial, 2-month, 1 year, and yearly follow-up
isits thereafter up to 5 years.
easurements. CHF AND ANGINA STATUS. The NYHA-
C, assessing CHF symptoms of dyspnea and fatigue, and
CS-AC, assessing anginal chest pain, were defined by
tandard scales, with the addition of a class 0 in each scale
o signify no symptoms of CHF or angina (12–14,25,28).
nitial assessments were made at the time of randomization
r during an initial visit within 14 days of randomization. In
atients who were randomized while hospitalized, status
as assessed at discharge. Both the NYHA-FC and
CS-AC were assessed at each follow-up visit (two
onths, four months, and every four months thereafter up
o five years).
OGNITIVE FUNCTION. The MMSE, a brief, quantified
ssessment of cognitive state, evaluates orientation, registra-
ion, attention, memory, and the ability to name, follow
erbal and written commands, write a sentence, and copy a
omplex figure (19–21). The examination is scored on a
0-point scale. Higher scores indicate better performance.
asks that could not be attempted because of physical
mpairment (e.g., vision, hearing, severe arthritis) were not
dded to the total score. Tasks that could not otherwise be
ttempted or completed were scored 0.
-MIN WALK TEST. Six-minute walking tests were con-
ucted in the standardized fashion (1,29–34). Distance
alked during 6 min of self-paced walking and standing
eart rates at baseline and at the end of the walk were
ecorded.
ample size. Sample size calculations for the functional
tatus subpopulation were computed based on the MMSE
ith 80% power to detect a 10% difference in scale (three
oints) and on the 6-min walk test with 80% power to
etect a 25 meter (82 feet) difference. For both calculations,
he required sample size to detect differences of this mag-
itude was fewer than 50 patients.
tatistical analysis. The primary analysis was an unad-
usted intention-to-treat comparison between rate-control
nd rhythm-control strategies for NYHA-FC, CCS-AC,
-min walk test distance, and MMSE scores. Additionally,
ntention-to-treat comparisons were performed adjusting
or imbalances of baseline covariates. Data also were ana-
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November 15, 2005:1891–9 Functional Status in the AFFIRM Studyyzed by the actual rhythm present at the time of evaluation
n adjusted analyses not including treatment arm. Covariates
sed in adjusted models included prespecified subgroups
age, qualifying AF episode being the first episode of AF,
ender, rhythm at randomization, duration of qualifying
pisode 2 days, normal left ventricular ejection fraction
LVEF], presence of coronary artery disease [CAD], history
f CHF or hypertension), as well as other variables that
ould be related to functional status (history of stroke or
ransient ischemic attack, diabetes, smoking, and college
ducation). Data are reported as mean  standard deviation
nless otherwise noted. Differences were considered statis-
ically significant at p values 0.05.
Baseline characteristics were compared with the chi-
quare and Student t tests. Analyses using all visits were
ased on repeated measures models. These statistical anal-
ses used generalized estimating equations, a statistical
echnique that combines all longitudinal data into one
odel and accounts for the nonindependence of within-
atient observations (35). The correlation structure for
ithin-patient observations was assumed to be exchangeable
all off-diagonal elements equal). Unadjusted analyses of all
ariables but NYHA-FC and CCS-AC included visit as a
ategorical variable so we could analyze group differences.
ecause of the greater number of visits with assessments of
YHA-FC and CCS-AC, unadjusted analyses of these
ariables used time as a continuous variable, based on
ears since randomization. Adjusted analyses used a
imilar continuous variable for the time effect and as-
essed change over the course of time by including
wo-way interaction terms.
ESULTS
rom 213 sites, 4,060 patients were enrolled in the
FFIRM study (24); 245 patients participated in the
unctional status substudy. Functional status substudy anal-
ses excluded 19 patients enrolled at substudy sites who
eclined to participate in functional status assessments. All
FFIRM study patients (n  4,060) participated in
YHA-FC and CCS-AC assessments at each visit.
atient characteristics. Functional status substudy subjects
ere similar to the rest of the AFFIRM study population
Table 1), except that compared with subjects not in the
ubstudy, the substudy group had a lower percentage of
emales (33% vs. 40%, p 0.03) and ethnic minorities (7% vs.
2%, p  0.04) and a higher proportion with warfarin use at
aseline (93% vs. 84%, p  0.0003), previous antiarrhythmic
rug failure (25% vs. 17%, p  0.002), and class IA antiar-
hythmic drug use (14% vs. 7%, p  0.0007). No significant
ifferences between rate and rhythm control groups were
resent in the total AFFIRM study group (24) nor in the
ubstudy (Table 1, p values all 0.05). Mean follow-up time
as 3.60  1.2 years for patients in the substudy and 3.48 
.3 years for the entire AFFIRM study. The number and
ercentage of substudy patients in sinus rhythm at their final fisit were 45 of 125 (36%) in the rate-control and 78 of 120
65%) in the rhythm-control arms (chi-square p  0.0001).
YHA-FC. INTENTION-TO-TREAT UNADJUSTED ANALYSIS.
ean NYHA-FC worsened significantly over the course of
ime in both rate-control and the rhythm-control arms of the
ntire study (n 4,060, p 0.0001) (Fig. 1A). No significant
ifferences were observed between treatment arms across all
isits or at any specific visit.
NTENTION-TO-TREAT ADJUSTED ANALYSIS. Adjusted
nalysis of NYHA-FC across all visits demonstrated no
ignificant differences between rate-control and rhythm-
ontrol patients. Covariates significantly associated with
orse NYHA-FC across all visits included history of CHF
p  0.0001), age 65 years (p  0.0005), diabetes (p 
.0017), abnormal LVEF (p  0.0001), and CAD (p 
.0001). History of CHF was significantly associated with
orsening NYHA-FC over the course of time (p 
.0045).
DJUSTED ANALYSIS BY CURRENT RHYTHM. Adjusted anal-
sis of NHYA-FC across all visits including current rhythm
AF or sinus rhythm) at each visit demonstrated that current
F was significantly associated with worse NYHA-FC
p  0.0001, 95% confidence interval 0.0770 to 0.1218)
Fig. 1B). Other significant covariates included CHF (p 
.0001), age 65 years (p  0.0074), male gender (p 
.0001), diabetes (p  0.0019), abnormal LVEF (p 
.0001), and CAD (p  0.0001). History of CHF was the
nly covariate significantly associated with worsening
YHA-FC over the course of time (p  0.0055).
CS-AC. INTENTION-TO-TREAT UNADJUSTED ANALYSIS. In
he AFFIRM study, only 9% of rate-control and 10% of
hythm control patients had anginal symptoms at the initial
isits. There were no significant differences between the two
reatment arms across all visits or at any specific visit.
NTENTION-TO-TREAT ADJUSTED ANALYSIS. Covariates
ignificantly associated with worse CCS-AC included his-
ory of CAD (p  0.0001), duration of qualifying episode
2 days (p  0.0001), diabetes (p  0.0093), CHF (p 
.0001), and prior stroke or transient ischemic attack (p 
.024). The CCS-AC did not significantly change over the
ourse of time, and no variables were significantly associated
ith change over the course of time. Treatment arm was not
ignificantly associated with CCS-AC across all visits or
ver the course of time.
DJUSTED ANALYSIS BY CURRENT RHYTHM. In adjusted
odels including current rhythm at each visit, presence of
F was not significantly associated with CCS-AC.
ognitive function: MMSE INTENTION-TO-TREAT UN-
DJUSTED ANALYSIS. At the initial visit, the mean MMSE
cores were higher for rate-control (28.3  2.2) compared
ith rhythm-control (27.3  2.6; p  0.0054) (Table 2).
here were no significant differences between arms at anyollow-up visit or across all visits.
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Functional Status in the AFFIRM Study November 15, 2005:1891–9NTENTION-TO-TREAT ADJUSTED ANALYSIS. College edu-
ation was the only covariate significantly associated with
MSE. Patients with college education scored higher, on
verage, than those without (p  0.0001). Age was the only
ignificant covariate associated with change in MMSE score
ver the course of time (p  0.02). Patients 65 years old
xperienced a decrease of 0.28 points per year more than
atients 65 years of age.
DJUSTED ANALYSIS BY CURRENT RHYTHM. Current AF
t each visit was not a significant covariate (Table 2).
arfarin use was not significantly associated with
MSE scores.
unctional capacity: 6-min walk test distance. INTENTION-
O-TREAT UNADJUSTED ANALYSIS. Average walk distance
ncreased with time in both treatment strategies (Fig. 2A).
able 1. Baseline Patient Characteristics
All Patients
(n  4060)
Patients
in FS
(n  245, 6%)
reatment arm
Rate-control 2,027 (50) 125 (51)
Rhythm-control 2,033 (50) 120 (49)
ge, yrs (mean  SD) 69.7  9.0 69.8  8.8
ge 65 yrs 3,091 (76) 196 (80)
ender, female sex 1,594 (39) 80 (33)
thnic minority group 461 (11) 18 (7)
redominant cardiac diagnosis
CAD 1,059 (26) 62 (25)
Cardiomyopathy 194 (5) 8 (3)
HTN 2,063 (51) 133 (54)
Valvular disease 198 (5) 8 (3)
Other 42 (1) 6 (2)
o apparent heart disease 504 (12) 28 (11)
istory of CHF 939 (23) 51 (21)
istory of CAD 1,551 (38) 93 (38)
istory of diabetes 813 (20) 47 (19)
istory of stroke 542 (13) 26 (11)
istory of smoking 496 (12) 31 (13)
VEF (mean  SD) 54.7  13.5 53.6  12.4
ormal LVEF 2,244 (74) 136 (75)
oderate-severe LV dysfunction 396 (13) 23 (13)
ormal left atrial size 1,103 (35) 63 (35)
arfarin use at baseline 3,434 (85) 227 (93)
revious antiarrhythmic drug failure 713 (18) 61 (25)
uration of qualifying AF episode
2 days 2,808 (69) 170 (69)
ualifying episode first AF episode 1,391 (36) 75 (32)
n AF at baseline 1,554 (38) 104 (42)
rug started or continued
Class I 524 (17) 40 (22)
Class IA 239 (8) 26 (14)
Class IC 273 (9) 13 (7)
Class III 1,348 (43) 72 (39)
Calcium channel blocker 1,025 (32) 55 (29)
Beta-adrenergic blocker 1,196 (38) 80 (41)
Digoxin 1,377 (43) 81 (43)
(%) except where noted. *p value reflects comparison of patients in FS substudy to pa
,650 rate-control, 1,661 rhythm-control; functional status substudy: 100 rate-control, 100 rh
VEF were unknown in 335 patients (65 functional status patients). Normal LV function w
AF  atrial fibrillation; CAD  coronary artery disease; CHF  congestive hea
VEF  left ventricular ejection fraction; SD  standard deviation.hythm-control patients walked significantly more distance an average, compared with rate-control patients with dif-
erences of 118 feet more at the initial visit, 124 feet at two
onths and 124 feet at one year. Averaging across all visits,
ifferences between the rate-control and the rhythm-control
rms were borderline significant (p  0.06), with rhythm-
ontrol patients walking on average 100 feet (8.5%) more
han rate-control patients.
NTENTION-TO-TREAT ADJUSTED ANALYSIS. In adjusted
nalysis, walk distance across all visits was significantly and
ndependently associated with treatment arm (p  0.049,
5% confidence interval 0.4158 to 188.57 feet). Average
alk distance was 94 feet (5.8%) more in the rhythm-
ontrol arm. Other significant covariates included diabetes
192 fewer feet, p  0.0015), gender (females 187 fewer
eet, p  0.0006), CHF (228 fewer feet, p  0.0001), and
Patients
p Value*
FS Patients
Rate-Control
(n  125)
FS Patients
Rhythm-Control
(n  120)
Not in FS
n  3815, 94%)
0.72
1,902 (50)
1,913 (50)
69.7  9.0 0.91 69.8  9.4 69.9  8.3
2,895 (76) 0.14 102 (82) 94 (78)
1,514 (40) 0.03 45 (36) 35 (29)
443 (12) 0.04 8 (6) 10 (8)
0.13
997 (26) 33 (26) 29 (24)
186 (5) 4 (3) 4 (3)
1,930 (51) 68 (54) 65 (54)
190 (5) 1 (1) 7 (6)
36 (1) 4 (3) 2 (2)
476 (12) 15 (12) 13 (11)
888 (23) 0.38 24 (19) 27 (23)
1,458 (38) 0.94 52 (42) 41 (34)
766 (20) 0.73 27 (22) 20 (17)
516 (14) 0.19 12 (10) 14 (12)
465 (12) 0.83 14 (11) 17 (14)
54.8  13.5 0.51 56.1  11.1 50.6  13.4
2,108 (74) 0.82 70 (78) 66 (72)
373 (13) 0.86 7 (8) 16 (17)
1040 (35) 0.85 30 (34) 33 (35)
3,207 (84) 0.0003 119 (95) 108 (90)
652 (17) 0.002 30 (24) 31 (26)
2,638 (69) 0.94 87 (70) 83 (69)
1,316 (36) 0.18 39 (32) 36 (31)
1,450 (38) 0.17 62 (50) 42 (35)
484 (16) 0.06 40 (36)
213 (7) 0.0007 26 (33)
260 (9) 0.41 13 (12)
1,276 (43) 0.26 72 (65)
970 (33) 0.26 45 (38) 10 (13)
1,116 (37) 0.26 61 (52) 19 (25)
1,296 (43) 0.76 54 (46) 27 (36)
not in substudy. Echocardiograms were obtained in 3,311 patients (overall AFFIRM study:
ontrol). Left atrial size was unknown in 242 (71 functional status patients); LV function and
ned as LVEF 50% and moderate-severe LV dysfunction as LVEF 40%.
ure; FS  Functional Status substudy; HTN  hypertension; LV  left ventricle;(
tients
ythm-c
as defige 65 years (133 more feet, p  0.023).
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November 15, 2005:1891–9 Functional Status in the AFFIRM StudyDJUSTED ANALYSIS BY CURRENT RHYTHM. Walk distance
t each visit by current rhythm is shown in Figure 2B. In
djusted models, AF at each visit was not significantly
ssociated with distance walked.
unctional capacity: 6-min walk test heart rates.
NTENTION-TO-TREAT UNADJUSTED ANALYSIS. Mean pre-
alk heart rates were significantly higher in the rate-
ontrol compared with rhythm-control group across all
igure 1. New York Heart Association functional class (NYHA-FC). M
reatment. (B) Current atrial fibrillation (AF) status: current AF versus no c
rom repeated measures analyses across all visits. N.S. not significant.isits (average difference 3.6 beats/min, p  0.0058). bre-walk heart rates in both groups decreased over the
ourse of time (Table 3).
Mean post-walk heart rates in both rate-control and
hythm-control arms also decreased over time, decreasing on
verage 0.98 beats/min per year across both treatment groups
p  0.025) (Table 3). Treatment group differences were not
ignificantly different at any visit or across all visits. Change in
eart rate during walk tests was not significantly different
NYHA-FC at each visit. (A) Rate- versus rhythm-control randomized
t AF present at visit. The p values reflect comparisons between two groupsean
urrenetween treatment strategies.
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Functional Status in the AFFIRM Study November 15, 2005:1891–9NTENTION-TO-TREAT ADJUSTED ANALYSIS. In adjusted
nalyses, pre-walk heart rates were significantly higher in
he rate-control compared with rhythm-control group (av-
rage difference 3.6 beats/min, p  0.004), but there were
o significant differences between groups in post-walk heart
ates.
DJUSTED ANALYSIS BY CURRENT RHYTHM. Including cur-
ent rhythm in adjusted models, AF was associated with
igher pre-walk (mean 11.5 beats/min higher, p  0.0001)
nd post-walk (mean 12.7 beats/min higher, p  0.0001)
eart rates.
ISCUSSION
he AFFIRM study reported no significant survival
enefits achieved from a rhythm-control compared with
ate-control strategy in patients with AF and showed
enefit for continuous anticoagulation with either treat-
ent strategy (24). In the absence of a survival difference
nd with persisting necessity for anticoagulation, major
easons to treat AF may include relief of symptoms and
igure 2. Six-minute walk test distance. (A) Rate- versus rhythm-control
andomized treatment. (B) Current atrial fibrillation (AF) status: current
F versus no current AF present at visit. The p values reflect comparisons
etween two groups from repeated measures analyses across all visits.improvement in functional status. In the current study,Ta
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November 15, 2005:1891–9 Functional Status in the AFFIRM Studyodestly longer 6-min walk distances were noted with
he rhythm-control strategy. The presence of AF was
ignificantly associated with worse NYHA-FC and
igher heart rates. However, no difference in cognitive
unction was detected.
YHA-FC. The NYHA-FC slightly increased over time
n both rate- and rhythm-control patients. Although no
ignificant differences between treatment groups were ob-
erved in NYHA-FC, the presence of current AF at
ollow-up visits was significantly associated with worse
YHA-FC. Part of this paradox between the goal of
aintaining sinus rhythm and the actual presence of sinus
hythm may be related to the inefficacy of antiarrhythmic
rugs to achieve their goal of maintaining sinus rhythm.
CS-AC. Angina pectoris was uncommon in AFFIRM,
onsistent with other studies showing chest pain to be an
ncommon symptom in AF (36). Few patients in the
FFIRM study had angina at the beginning of the study.
o differences in angina classification were detected be-
ween treatment groups.
ognitive function. Adjusted MMSE scores did not differ
ignificantly between treatment groups, in analyses based on
ctual rhythm present at follow-up, or after adding warfarin
se to the analyses.
Age, although not previous CVA, was associated with
hange in scores over time. In a previous study of elderly
atients with nonvalvular chronic AF, age and number of
acunar lesions were associated with lower MMSE scores
22). Previous reports of cognitive dysfunction associated
ith AF studied patient cohorts in which the use or dose of
nticoagulation was low (22,37–39). Although there was a
ifference in anticoagulation use between the randomized
rms of the AFFIRM study, anticoagulation use was high
able 3. Heart Rates for Six-Minute Walk Test at Initial and Fo
Initial 2 M
ate-Control Versus Rhythm-Control Treatment Arm
Rate 109
Rhythm 105
R pre-walk Rate 75.8  16 73
p  0.0057 Rhythm 74.0  16 67
R post-walk Rate 95.2  24 89
p  0.13 Rhythm 93.8  19 86
R post-walk-HR pre-walk Rate 19.3  15 16
p  0.45 Rhythm 19.8  14 18
urrent AF Status
No 119
Yes 95
R pre-walk No 68.1  12 65
p  0.0001 Yes 83.5  16 77
R post-walk No 85.8  17 82
p  0.0001 Yes 105.5  23 95
R post-walk-HR pre-walk No 17.6  12 17
p  0.0061 Yes 22.0  16 18
ll p values reflect group differences across all visits from unadjusted generalized est
HR  heart rate in beats/min.verall, with no significant difference in stroke rates between (roups, which may explain the lack of detection of differ-
nces in cognitive function in AF patients, if these differ-
nces depended upon the relative incidences of cerebrovas-
ular events.
alk testing. Functional status, as measured by 6-min
alk test distance, improved in both treatment arms. Walk
istance across all visits was modestly although significantly
onger in the rhythm-control group. These results are
imilar to those reported in the Pharmacological Interven-
ion in Atrial Fibrillation (PIAF) study (18) of 252 patients
andomized to rate versus rhythm-control. Walk distances
ere on average shorter in the AFFIRM study, but the
FFIRM study population was older (mean age 70 years)
han in PIAF (mean age 60 years). Although there appeared
o be a trend toward longer walk distances in patients in
inus rhythm compared with AF up through year 2, this
ifference was not sustained at years 3 and 4. The reason for
his is unclear, particularly as prewalk and postwalk heart
ate control did not appear worse on average at later years,
lthough differences in the type of medications used in the
ate- and rhythm-control groups could have been
ontributory.
Whether the mean difference of approximately 100 feet
8.5%) between rate-control and rhythm-control walk dis-
ance is clinically significant is uncertain. In a study of 45
lder patients with CHF, the mean difference in 6-min walk
istance associated with clinical differences in patient per-
eption of worsening was 43 meters (141 feet) (17). In
tudies of biventricular pacing in heart failure patients,
linical benefit was reported with 6-min walk distance
ifferences of 29 meters (95 feet) in the Multicenter InSync
andomized Clinical Evaluation (MIRACLE) trial (40)
nd 38.5 meters (126 feet) at three months and 42 meters
-Up Visits
hs 1 Year 2 Years 3 Years 4 Years
95 65 46 32
83 63 53 25
3 72.9  11 72.9  13 69.4  10 68.8  10
2 67.1  13 68.8  15 68.4  13 72.4  14
7 89.9  15 90.4  17 86.8  14 86.3  15
7 86.4  18 86.7  18 85.5  20 87.5  18
1 17.0  11 17.4  11 17.4  10 17.5  12
2 19.3  14 17.9  11 17.1  15 15.0  13
99 72 60 24
79 56 39 33
1 65.4  11 65.5  12 66.2  12 64.0  10
2 76.3  11 77.8  14 72.9  10 75.1  11
7 83.0  16 81.6  14 82.6  19 81.2  16
5 94.9  16 97.6  18 91.6  13 90.9  15
2 17.6  13 16.1  10 16.4  13 17.2  15
1 18.6  11 19.8  12 18.7  11 15.9  10
g equations analyses, including visit as a categorical variablellow
ont
98
96
.2  1
.5  1
.8  1
.1  1
.6  1
.6  1
112
82
.3  1
.2  1
.6  1
.4  1
.3  1
.1  1138 feet) at six months in the Comparison of Medical
T
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COMPANION) trial (41). Among studies reporting dif-
erences as a percentage of walk distances, benefits with
iventricular pacing range from 17% to 32%, corresponding
o walk distance differences of 29 to 93 meters (95 to 305
eet) (39,42–44). Detection of changes in 6-min walk
istances may be restricted by limited responsiveness of the
easure (45).
Pre-walk heart rates were significantly higher in the
ate-control arm. Moreover, current AF was strongly asso-
iated with both higher pre-walk and post-walk heart rates
ompared with sinus rhythm. These differences persisted
ver time and could have contributed to the shorter walk
istances observed in patients in the rate-control group. It is
nclear whether targeting to lower heart rate levels would
ave improved walk distances or achieved other functional
tatus benefits in the rate control strategy. Moreover, it is
ncertain whether higher heart rates or AF itself led to the
ifferences observed in walk distance or functional class.
tudy limitations. Several factors may have affected the
mpact of treatment strategies on functional status. Patients
ith frequent or severe AF symptoms may not have been
nrolled, and it is unknown how more symptomatic patients
ould have responded to treatment strategies. It is also
ossible that more-stringent heart rate control in the rate
ontrol arm would have achieved better functional status.
True baseline assessment of functional status before
andomization was not available in all patients because
nitial visits for functional status assessments were dissimilar
o randomization dates in 34% of patients. At initial
unctional status visits, 52% of rate-control and 35% of
hythm-control patients were in AF (p 0.012), suggesting
n effect of prescribed treatment before initial functional
tatus assessment. Thus, changes in functional status pa-
ameters from initial assessments cannot necessarily infer
hange from a baseline prerandomization state. This limi-
ation may particularly be true for walk test results.
Relative insensitivity of the MMSE to detect changes in
ognitive function, especially near the higher end of the
cale, may have limited these results. However, this instru-
ent was a standard measure of cognitive function at the
ime when the AFFIRM study was designed. Finally, in the
FFIRM study, assessments were not blinded. It is possible
hat knowledge of the randomized strategy or the presence
f AF resulted in biased functional status evaluations.
onclusions. The NYHA-FC gradually worsened with
ime in both rate and rhythm-control groups and was
ignificantly worse if AF was present at follow-up. Six-min
alk test distance improved over the course of time in
atients treated with either strategy and was modestly
onger in the rhythm-control patients. Higher resting pre-
alk heart rates were observed in rate-control strategy
atients; pre-walk and post-walk heart rates were higher in
atients with current AF at testing. It is unclear whether
ower heart rate targets in the rate control strategy would
ave improved walk distances. Cognitive function, as mea-ured by MMSE scores, did not significantly differ over the
ourse of time in patients treated with either strategy.
lthough a rhythm-control approach used to treat AF does
ot improve survival, this strategy might be appropriate for
atients with AF who remain symptomatic despite rate
ontrol, as some incremental improvement in functional
tatus may be achievable.
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